Key Players
Competitive Landscape
Supplier competition across the dough relaxants landscape spans primary biotechnology enzyme fermenters, global bakery improver formulators, and adjacent emulsifier manufacturers. Biotech specialists Novonesis and AB Enzymes with Kerry Group and dsm-firmenich ferment bacterial and fungal endo-proteases that selectively cleave gluten peptide bonds and reduce dough viscosity. Improver houses including IFF and Corbion with Puratos and Amano Enzyme blend proteases with deactivated glutathione yeast and carrier starches tailored to regional wheat harvests. Adjacent ingredient suppliers Palsgaard and BASF provide cake aerating emulsifiers and polyglycerol esters. Industrial bakery R&D directors qualify suppliers on thermal inactivation precision and lot-to-lot activity stability.
Engineering enzymatic dough relaxation systems that replace chemical reducing agents while expanding regional pilot-testing laboratories has become the central competitive battleground for baking biosolutions providers. Rather than selling standalone commodity enzymes, suppliers are investing in regional application centers equipped with pilot sheeting lines and rheological analyzers to calibrate protease dosing on local flour grists. In May 2026, food scientists publishing in the Journal of Food Science demonstrated that enzymatic hydrolysis using neutral protease and trypsin regulates protein-lipid interactions and honeycomb crumb structure in biscuit doughs [22]. Strengthening regulatory and enzymatic credentials across Europe, Kerry Group reported EUR 6.76 billion in 2025 revenue with 3.5% volume growth in Food EUM in February 2026 [21] and secured a positive EFSA scientific opinion for its Acrylerase enzyme in May 2026 [23]. Meanwhile, Novonesis launched its Optiva LS Prime enzymatic baking solution in June 2025 [19] and Palsgaard inaugurated a advanced bakery application center in Navi Mumbai in July 2025 [20].
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| June 2026: AB Enzymes opened a new regional office and baking lab in Curitiba, Brazil [7]. | South American wheat harvests exhibit wide seasonal protein and elasticity swings. | Enzyme producers build localized pilot-testing labs to calibrate dosage on regional flours. | On-site Farinograph and sheeting validation secures multi-year mill and bakery contracts. |
| May 2025: dsm-firmenich opened its Princeton Baking Innovation Center in New Jersey [14]. | North American bun and cracker plants require rapid sulfite-free dough conditioning trials. | Ingredient suppliers integrate enzyme fermentation science with pilot-scale bakery lines. | Co-developed protease and xylanase blends capture direct industrial bakery accounts. |
| May 2025: Puratos launched concentrated Cubease pre-dosed bakery improver cubes at iba 2025 [4]. | Industrial bakeries face manual micro-ingredient weighing errors and high freight costs. | Improver formulators compress active enzymes into solid unit-dose formats. | Pre-measured improver cubes streamline multi-plant dosing and reduce packaging waste. |
| July 2025: Palsgaard inaugurated its Navi Mumbai bakery application center in India [20]. | Emerging-market bakeries require localized technical service for texture optimization. | Specialty ingredient groups expand regional pilot bakeries across Asia-Pacific. | Application labs support cross-selling of complementary emulsifiers and dough conditioners. |
Source: Future Market Insights, Dough Relaxants Market Report, 2026-2036.
Recent laboratory openings and unit-dose launches confirm that winning industrial dough relaxant accounts requires pairing narrow-specificity proteases with localized pilot-plant calibration. Suppliers that validate zero pan-shrink with clean-label sulfite elimination are projected to capture recurring direct supply agreements across multinational bakery chains.
How are key market participants positioned in the dough relaxants market?
Novonesis and AB Enzymes with Kerry Group and dsm-firmenich lead in primary bacterial and fungal protease fermentation for direct gluten relaxation. IFF and Corbion with Puratos and Amano Enzyme formulate multi-component bakery improvers, while Palsgaard and BASF supply adjacent emulsifiers and cake aeration ingredients.
What qualification or purchasing requirements matter most to prospective buyers?
Industrial bakery technical directors require verified Extensograph and Alveograph dose-response curves proving that gluten elasticity drops without sacrificing gas retention or loaf volume. Buyers also mandate sharp thermal inactivation at 60 to 65 degrees Celsius and full EFSA or FDA GRAS processing-aid documentation.
Which product or application capabilities distinguish the leading companies?
Primary enzyme producers differentiate through proprietary Bacillus subtilis and Aspergillus oryzae strains that cleave internal peptide bonds cleanly without producing bitter peptides or sticky dough. Improver houses excel in unit-dose delivery systems such as Puratos Cubease and pre-blended deactivated glutathione yeast premixes.
How does geographic reach differ among the key market players?
Novonesis and IFF with Kerry Group and AB Enzymes operate multi-continent fermentation plants and regional baking laboratories across Europe, the Americas, and Asia-Pacific. Amano Enzyme anchors specialty non-GM enzyme supply in Japan, while Puratos and dsm-firmenich with Corbion maintain broad industrial bakery technical networks.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Novonesis | Global biosolutions leader supplying Neutrase bacterial endo-proteases for biscuit, cracker, and bakery relaxation. | Launched Optiva LS Prime enzymatic baking solution in June 2025 [19] and received EFSA xylanase extension evaluation in July 2026 [10]. |
| IFF | Global food biosciences and enzyme producer supplying Danisco bakery enzymes and hydrocolloids. | Published industrial dough-conditioning enzyme framework in May 2025 [3] and completed EFSA maltohydrolase evaluation in May 2026 [16]. |
| Kerry Group | Global taste and nutrition company producing Biobake enzymes and clean-label dough improvers. | Reported EUR 6.76 billion 2025 revenue in February 2026 [21] and published bakery enzyme cost-performance analysis in March 2026 [15]. |
| AB Enzymes | Industrial biotech subsidiary of Associated British Foods manufacturing VERON baking proteases and xylanases. | Opened a new regional office and baking application laboratory in Curitiba, Brazil in June 2026 [7]. |
| Amano Enzyme | Japanese specialty enzyme manufacturer producing non-GM fungal and bacterial proteases for food processing. | Supplies precision proteolytic and amylolytic enzyme preparations across East Asian and global bakery accounts. |
| Palsgaard | Danish specialist in plant-based bakery emulsifiers, cake gels, and crystal-stabilizing lipids. | Inaugurated a advanced bakery application center in Navi Mumbai, India in July 2025 [20]. |
| Corbion | Global supplier of lactic acid derivatives, functional enzyme blends, and clean-label bread improvers. | Presented clean-label bakery reformulation and dough conditioning technologies at IBIE 2025 in September 2025 [6]. |
| BASF | Global chemical company supplying Spongolit cake aerating emulsifiers and whipping bases. | Participates via adjacent cake batter aeration systems following the divestiture of its Nutrilife baking enzymes line to Lallemand. |
| Puratos | International bakery, patisserie, and chocolate ingredient group supplying S500 and Cubease improvers. | Launched concentrated Cubease unit-dose bakery improver technology at iba 2025 in May 2025 [4]. |
| dsm-firmenich | Global nutrition and bioscience group manufacturing BakeZyme proteases, xylanases, and lipases. | Opened its Princeton Baking Innovation Center in Princeton, New Jersey in May 2025 [14]. |
Research Methodology
Quantifying the dough relaxants market combined primary cereal-chemistry interviews with regulatory dossier reviews and top-down and bottom-up triangulation. Volume-to-value modeling converts treated commercial bakery flour tonnage (52.5 million to 59.0 million metric tons in 2026) into active ingredient expenditure using verified 10 to 90 ppm L-cysteine/glutathione and 2 to 27.5 mg TOS/kg flour enzymatic dosing schedules across bread and biscuit lines. Final figures isolate the extensibility and gluten-relaxation function and exclude parent baking ingredients and oxidizing dough strengtheners with standalone crumb-softening amylases.
